# BPC-157 Reviewed: Angiogenesis, Tissue Repair, and the Honest Evidence Record > BPC-157, a stable 15-amino-acid gastric pentadecapeptide, has driven angiogenesis and tissue repair across preclinical models. A confidence-graded digest, cited to source. A reviewed digest of the VEGFR2-Akt-eNOS mechanism, the dose-context data, and the three small human pilots. Every claim carries a confidence grade and a citation. ## What the BPC-157 record actually establishes BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Across three decades of preclinical work it has been studied for one recurring property: accelerated tissue repair, most consistently linked to angiogenesis — the formation of new blood vessels [3]. This site reviews that record and grades it. Findings the animal and cell literature genuinely establishes are marked ESTABLISHED; the tiny human dataset is marked PILOT-ONLY; the gaps are marked NO HUMAN DATA. The grading is the point. A review's job is to say not just what was found, but how far the finding reaches. The best-characterized mechanism is pro-angiogenic. BPC-157 up-regulates and internalizes the VEGFR2 receptor and activates the downstream VEGFR2-Akt-eNOS (nitric-oxide) pathway [3]. That single mechanism is the thread connecting its reported effects on tendon, gut, vasculature, and other tissues, which is why this digest reads the literature through it rather than as a scatter of unrelated results. We treat it as the unifying lens, covered in depth on the [BPC-157 angiogenesis research](/angiogenesis) page. The foundational repair findings are reproducible and specific. In a fully transected rat Achilles tendon, BPC-157 improved biomechanical, functional, and microscopic recovery against untreated controls [1]. In rat gastric-ulcer models it cut ulcer area and accelerated healing, with intramuscular delivery outperforming intragastric and an ulcer-formation inhibition ratio reaching roughly 45.7-65.6% at the higher doses [4]. These are animal results, measured across multiple endpoints rather than a single proxy — and that specificity is exactly what makes them worth grading rather than hand-waving. What the record does not contain is just as important to the review. There is no controlled human efficacy trial, no FDA-approved human indication, and no validated human dose [12]. The honest summary is a strong, internally consistent preclinical body of work paired with a human dataset still measured in single studies — and a digest worth reading states both halves in the same breath. ## BPC-157 as a stable gastric pentadecapeptide BPC-157 is a stable gastric pentadecapeptide — the descriptor its own authors use, because the molecule is reported stable in human gastric juice. As a BPC-157 peptide it carries the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a molecular formula of C62H98N16O22, and a molecular weight of 1419.53 Da. It is not a hormone and not a growth factor; it is a short peptide that, in animals, is broken down quickly into ordinary amino-acid fragments that re-enter normal metabolism [2]. That stability claim is why oral and peroral routes draw interest, and animal ulcer work has dosed the peptide intragastrically [4]. But formal human oral pharmacokinetics have never been characterized, so 'stable in the stomach' is an established laboratory property, not a demonstrated route to a clinical effect in people. ## Where the human evidence stops The honest headline is small: as of 2025 reviews, only three small human pilot studies exist [12]. A two-person intravenous safety pilot reported no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers across 10 mg and 20 mg infusions [11]. An uncontrolled knee-pain case series reported reduced pain after intra-articular injection [10]. A 12-patient intravesical pilot reported symptom resolution in most patients with interstitial cystitis [13]. Every one of these is uncontrolled or tiny. None establishes efficacy, and the safety pilot — encouraging as it reads — enrolled exactly two people. This is the gap a reviewed digest exists to mark. It is tempting, with a decade of consistent rodent data, to round 'works in animals' up to 'works.' The grading on this site refuses that rounding. A finding measured carefully in Wistar rats is a finding about Wistar rats until a controlled human trial says otherwise, and for BPC-157 that trial does not yet exist [12]. The mechanism is well characterized in animals; the human chapter has barely begun. That is not a reason to dismiss the compound and not a reason to oversell it — it is a reason to read the evidence at the resolution it actually has. You can read the full evidence on [BPC-157 research findings](/research), study the three [human pilot studies](/research) in detail, see [how BPC-157 doses are expressed](/dosage) in the literature, and review the [BPC-157 legal status and 503A category](/legal-status) for where regulated access actually stands. ## How this digest grades its claims Five grades run through every page. ESTABLISHED marks what the animal and cell literature genuinely shows — the VEGFR2-Akt-eNOS angiogenesis mechanism [3], the transected-Achilles result [1], gastric-ulcer cytoprotection [4], and the first formal pharmacokinetic characterization [2]. PRECLINICAL marks rodent-only or in-vitro mechanism points that have not crossed into humans. PILOT-ONLY marks the three small human studies [11][10][13]. NO HUMAN DATA marks the genuine blanks: no controlled efficacy trial, no validated human dose, no human interaction profile [12]. REGULATORY marks the access boundaries — covered on [BPC-157 FDA 503A compounding status](/legal-status). One structural caveat sits across the whole record. A large share of the foundational literature comes from a single research group, which newer authors explicitly flag as a replication question [12]. A reviewed digest names that, rather than presenting concentrated evidence as if it were broad consensus. --- Each BPC-157 finding here is graded by how far the evidence actually reaches — established in animals, pilot-only in humans, or no human data at all — and the FDA 503A status is read first; reviewed by no clinic, and nothing here is dispensed or sold.